Barclays PLC Grows Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Barclays PLC lifted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,060 shares of the specialty pharmaceutical company's stock after buying an additional 14,027 shares during the quarter. Barclays PLC owned 0.75% of ANI Pharmaceuticals worth $8,682,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Exchange Traded Concepts LLC lifted its holdings in ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after acquiring an additional 310 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares during the period. Natixis Advisors LLC grew its position in ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after buying an additional 417 shares during the period. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the period. Finally, KBC Group NV lifted its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at $5,526,799.20. The trade was a 0.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,200 shares of company stock valued at $197,792. Company insiders own 12.70% of the company's stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of research reports. Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday, April 11th. Truist Financial upped their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $80.13.

ANI Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ ANIP traded up $0.18 during midday trading on Friday, reaching $69.82. 205,402 shares of the stock were exchanged, compared to its average volume of 273,758. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.52 billion, a P/E ratio of -126.95 and a beta of 0.49. The stock has a 50 day moving average price of $64.24 and a 200-day moving average price of $59.86. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.55.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.